Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


31.10.2022

1 Ann Intern Med
1 Arch Pediatr
4 BMJ
1 J Gen Virol
3 J Infect
3 J Infect Dis
2 J Virol
1 JAMA
6 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
2 Nat Med
1 PLoS Med
8 PLoS One
2 Science
21 Vaccine
2 Virology
1 Virus Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. ROOZEN GVT, Prins MLM, van Binnendijk R, den Hartog G, et al
    Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
    Ann Intern Med. 2022 Oct 25. doi: 10.7326/M22-2089.
    PubMed        


    Arch Pediatr

  2. COLLIGNON C, Frachette C, Callot D, Pinhas Y, et al
    Two pediatric cases of multisystem inflammatory-like syndrome following COVID-19 vaccination.
    Arch Pediatr. 2022 Sep 26. pii: S0929-693X(22)00207.
    PubMed         Abstract available


    BMJ


  3. FDA urged to publish follow-up studies on covid-19 vaccine safety signals.
    BMJ. 2022;379:o2593.
    PubMed        

  4. WASSWA H
    Ebola: Uganda plans trials of two vaccines as cases rise.
    BMJ. 2022;379:o2589.
    PubMed        

  5. LI X, Burn E, Duarte-Salles T, Yin C, et al
    Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
    BMJ. 2022;379:e071594.
    PubMed         Abstract available

  6. DEMASI M
    FDA urged to publish follow-up studies on covid-19 vaccine safety signals.
    BMJ. 2022;379:o2527.
    PubMed        


    J Gen Virol

  7. ZHANG RY, Pallett MA, French J, Ren H, et al
    Vaccinia virus BTB-Kelch proteins C2 and F3 inhibit NF-kappaB activation.
    J Gen Virol. 2022;103.
    PubMed         Abstract available


    J Infect

  8. NISHIKIMI A, Nakagawa T, Fujiwara M, Watanabe K, et al
    Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00621.
    PubMed        

  9. KANDEL C, Lee Y, Taylor M, Llanes A, et al
    Viral Dynamics of the SARS-CoV-2 Omicron Variant Among Household Contacts with 2 or 3 COVID-19 Vaccine Doses.
    J Infect. 2022 Oct 22. pii: S0163-4453(22)00625.
    PubMed         Abstract available

  10. HE WQ, Gianacas C, Muscatello DJ, Newall AT, et al
    Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study.
    J Infect. 2022 Oct 23. pii: S0163-4453(22)00626.
    PubMed         Abstract available


    J Infect Dis

  11. DE SILVA A, White L
    Immunogenicity of a live dengue vaccine (TAK-003).
    J Infect Dis. 2022 Oct 26. pii: 6774399. doi: 10.1093.
    PubMed        

  12. ROE MK, Perez MA, Hsiao HM, Lapp SA, et al
    An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.
    J Infect Dis. 2022 Oct 25. pii: 6770706. doi: 10.1093.
    PubMed         Abstract available

  13. DOOLING K, Marin M, Gershon AA
    Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone.
    J Infect Dis. 2022;226.
    PubMed         Abstract available


    J Virol

  14. BRICE AM, Rozario AM, Rawlinson SM, David CT, et al
    Lyssavirus P Protein Isoforms Diverge Significantly in Subcellular Interactions Underlying Mechanisms of Interferon Antagonism.
    J Virol. 2022;96:e0139622.
    PubMed         Abstract available

  15. DING M, Dang W, Liu H, Zhang K, et al
    Sequential Deletions of Interferon Inhibitors MGF110-9L and MGF505-7R Result in Sterile Immunity against the Eurasia Strain of Africa Swine Fever.
    J Virol. 2022;96:e0119222.
    PubMed         Abstract available


    JAMA

  16. NAGGIE S, Boulware DR, Lindsell CJ, Stewart TG, et al
    Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    JAMA. 2022 Oct 21. pii: 2797483. doi: 10.1001/jama.2022.18590.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  17. MBAEYI C, Baig S, Safdar MR, Khan Z, et al
    Progress Toward Poliomyelitis Eradication - Pakistan, January 2021-July 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1313-1318.
    PubMed         Abstract available

  18. OLIVARES BARRAZA MF, Fasce RA, Nogareda F, Marcenac P, et al
    Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season - Chile, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1353-1358.
    PubMed         Abstract available

  19. KRISS JL, Boersma PM, Martin E, Reed K, et al
    Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox - United States, May 22-October 10, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1374-1378.
    PubMed         Abstract available

  20. MILLMAN AJ, Denson DJ, Allen ML, Malone JA, et al
    A Health Equity Approach for Implementation of JYNNEOS Vaccination at Large, Community-Based LGBTQIA+ Events - Georgia, August 27-September 5, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1382-1883.
    PubMed         Abstract available

  21. SOELAEMAN RH, Mendoza L, McDonald R, Hand J, et al
    Characteristics of JYNNEOS Vaccine Recipients Before and During a Large Multiday LGBTQIA+ Festival - Louisiana, August 9-September 5, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1379-1381.
    PubMed         Abstract available

  22. BLACK CL, O'Halloran A, Hung MC, Srivastav A, et al
    Vital Signs: Influenza Hospitalizations and Vaccination Coverage by Race and Ethnicity-United States, 2009-10 Through 2021-22 Influenza Seasons.
    MMWR Morb Mortal Wkly Rep. 2022;71:1366-1373.
    PubMed         Abstract available


    N Engl J Med

  23. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection.
    N Engl J Med. 2022;387:e50.
    PubMed        

  24. CHIN ET, Leidner D, Lamson L, Lucas K, et al
    Protection against Omicron from Vaccination and Previous Infection in a Prison System.
    N Engl J Med. 2022 Oct 26. doi: 10.1056/NEJMoa2207082.
    PubMed         Abstract available


    Nat Med

  25. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02064.
    PubMed         Abstract available

  26. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed         Abstract available


    PLoS Med

  27. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2022;19:e1003979.
    PubMed         Abstract available


    PLoS One

  28. GOULART ROSA R, Spinardi J, Allen KE, Manfio J, et al
    BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan.
    PLoS One. 2022;17:e0276384.
    PubMed         Abstract available

  29. KIM YR, Choi YJ, Min Y
    A model of COVID-19 pandemic with vaccines and mutant viruses.
    PLoS One. 2022;17:e0275851.
    PubMed         Abstract available

  30. TARIMO EAM, Ambikile J, Munseri P, Bakari M, et al
    Personal experiences following acquiring HIV infection while volunteering in Phase I/II HIV vaccine trials: A qualitative study from Tanzania.
    PLoS One. 2022;17:e0276404.
    PubMed         Abstract available

  31. CHERENACK EM, Salazar AS, Nogueira NF, Raccamarich P, et al
    Infection with SARS-CoV-2 is associated with menstrual irregularities among women of reproductive age.
    PLoS One. 2022;17:e0276131.
    PubMed         Abstract available

  32. ENDERS AM, Uscinski J, Klofstad C, Stoler J, et al
    On the relationship between conspiracy theory beliefs, misinformation, and vaccine hesitancy.
    PLoS One. 2022;17:e0276082.
    PubMed         Abstract available

  33. TOBOLOWSKY FA, Waltenburg MA, Moritz ED, Haile M, et al
    Longitudinal serologic and viral testing post-SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort-Georgia, October 2020April 2021.
    PLoS One. 2022;17:e0275718.
    PubMed         Abstract available

  34. ARUFFO E, Yuan P, Tan Y, Gatov E, et al
    Community structured model for vaccine strategies to control COVID19 spread: A mathematical study.
    PLoS One. 2022;17:e0258648.
    PubMed         Abstract available

  35. CONTRACTOR A, Shivaprakash S, Tiwari A, Setia MS, et al
    Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin (R)) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    PLoS One. 2022;17:e0276759.
    PubMed         Abstract available


    Science

  36. MAO T, Israelow B, Pena-Hernandez MA, Suberi A, et al
    Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.
    Science. 2022 Oct 27:eabo2523. doi: 10.1126/science.abo2523.
    PubMed         Abstract available

  37. COHEN J
    Forgotten Ebola vaccine could help in outbreak.
    Science. 2022;378:340-341.
    PubMed         Abstract available


    Vaccine

  38. TADDIO A, McMurtry CM, Logeman C, Gudzak V, et al
    Prevalence of pain and fear as barriers to vaccination in children - Systematic review and meta-analysis.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01287.
    PubMed         Abstract available

  39. PHOKSAWAT W, Nithichanon A, Lerdsamran H, Wongratanacheewin S, et al
    Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01265.
    PubMed         Abstract available

  40. SHU Y, Yu Y, Ji Y, Zhang L, et al
    Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01281.
    PubMed         Abstract available

  41. SERRA L, Webber C, Burman C, Bueti P, et al
    Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01197.
    PubMed         Abstract available

  42. BLANCO S, Spinsanti L, Javier Aguilar J, Diaz A, et al
    Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01283.
    PubMed         Abstract available

  43. RABE APJ, Costello P, Were JJ, Farrer A, et al
    The burden of selected vaccine-preventable diseases on the secondary care health system in England: Results from a five-year administrative healthcare dataset.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01263.
    PubMed         Abstract available

  44. MADEWELL ZJ, Chacon-Fuentes R, Badilla-Vargas X, Ramirez C, et al
    Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01284.
    PubMed         Abstract available

  45. KURATA T, Miyama T, Kanbayashi D, Kaida Y, et al
    Increasing seroprevalence but waning herd immunity against measles after elimination: Longitudinal seroepidemiology of measles in Osaka Prefecture, Japan, 2003-2020.
    Vaccine. 2022;40:6581-6588.
    PubMed         Abstract available

  46. BAMOUH Z, Hamdi J, Elkarhat Z, Fellahi S, et al
    Attenuation and genetic characteristics of a Moroccan strain of Camel pox virus.
    Vaccine. 2022;40:6471-6480.
    PubMed         Abstract available

  47. URUENA A, Ruiz JI, Lew DA, David J, et al
    Opinions, attitudes, and barriers to pediatric vaccination in Argentina.
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01256.
    PubMed         Abstract available

  48. PENG M, Joo J, Alvarado-Martinez Z, Tabashsum Z, et al
    Intracellular autolytic whole cell Salmonella vaccine prevents colonization of pathogenic Salmonella Typhimurium in chicken.
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01261.
    PubMed         Abstract available

  49. RHODES S, Smith N, Evans T, White R, et al
    Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01260.
    PubMed         Abstract available

  50. SAPUAN S, Andrews N, Hallis B, Hole L, et al
    An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-containing vaccines or received no pertussis-containin
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01243.
    PubMed         Abstract available

  51. LAI L, Rouphael N, Xu Y, Kabbani S, et al
    An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01146.
    PubMed         Abstract available

  52. HOSHI SL, Shono A, Seposo X, Okubo R, et al
    Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01259.
    PubMed         Abstract available

  53. ZHONG VW, Li X, Ran J, Hu G, et al
    Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01262.
    PubMed         Abstract available

  54. DUCLOS P, MacDonald NE, Dochez C, Thacker N, et al
    Report of the 2nd workshop of the International Collaboration on advanced vaccinology training.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01222.
    PubMed         Abstract available

  55. ARASA J, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A, et al
    Impact of rotavirus vaccination on seizure hospitalizations in children: A systematic review.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01228.
    PubMed         Abstract available

  56. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    PubMed         Abstract available

  57. SANTIBANEZ TA, Black CL, Vogt TM, Chatham-Stephens K, et al
    Where are children ages 5-17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01282.
    PubMed         Abstract available

  58. NAYAR R, Pattath B, Mantha N, Debnath S, et al
    Routine childhood vaccination in India from 2005-2006 to 2015-2016: Temporal trends and geographic variation.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01285.
    PubMed         Abstract available


    Virology

  59. LAMICHHANE P, Schmidt ME, Terhuja M, Varga SM, et al
    A live single-cycle RSV vaccine expressing prefusion F protein.
    Virology. 2022;577:51-64.
    PubMed         Abstract available

  60. TANG CY, Boftsi M, Staudt L, McElroy JA, et al
    SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021-2022 influenza season.
    Virology. 2022;576:105-110.
    PubMed         Abstract available


    Virus Res

  61. YAN LN, Li D, Wang ZD, Jiang ZZ, et al
    Neutralizing antibodies and T-cell responses to inactivated SARS-Cov-2 vaccine in COVID-19 convalescents one and a half years after infection.
    Virus Res. 2022 Oct 22:198977. doi: 10.1016/j.virusres.2022.198977.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: